 | |
 | |
| Clinical data | |
|---|---|
| Other names | Piperidine-4-carboxylic acid; P4C; 4-Piperidinecarboxylic acid; Hexahydroisonicotinic acid; 4-Carboxypiperidine |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.007.158 |
| Chemical and physical data | |
| Formula | C6H11NO2 |
| Molar mass | 129.159 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Isonipecotic acid, also known aspiperidine-4-carboxylic acid (P4C), is aconformationally constrainedderivative ofγ-aminobutyric acid (GABA) and a moderatelypotentGABAA receptorpartial agonist.[1][2][3] It consists of apiperidine ring with acarboxylic acidmoiety in theiso position.[1] The drug showed moderate-efficacy partial agonism of α1, α2, α3, and α5 subunit-containing GABAA receptors (EmaxTooltip maximal efficacy = 46–57%), but showedfull or near-full agonism of α4 and α6 subunit-containing GABAA receptors (Emax = 83–104%).[2] Isonipecotic acid is unable to cross theblood–brain barrier.[4] It was first described in thescientific literature by at least 1944[5] and was identified as a GABAA receptor agonist by 1978.[6]
Isonipecotic acid (Ib) was shown to be a potent and specific y-aminobutyric acid agonist in the [3H]y-aminobutyric acid-binding assay procedure (13,14). As in the case of nipecotic acid, isonipecotic acid was also too polar to penetrate the blood-brain barrier.
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |